15 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
31 May 22
Current report (foreign)
6:07am
treatment that prevented HAE attacks over an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic
6-K
TAK
Takeda Pharmaceutical Co
10 Feb 22
Current report (foreign)
6:03am
an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic subgroups. These data were presented
6-K
TAK
Takeda Pharmaceutical Co
5 Nov 21
Current report (foreign)
6:02am
over an extended planned 132 week treatment period across specific HAE patient demographic and disease characteristic subgroups. These data were
6-K
7dijy3
6 Aug 21
Current report (foreign)
6:06am
424B3
mqba4h g4sh6ux
14 Nov 19
Prospectus supplement
6:10am
F-4/A
erfbc6n93rltf0t4
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
F-4
tk2kd7wdnih dq
9 Aug 19
Registration of securities (foreign)
6:27am
20-F
tlk25hf
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
6hfehl wh3
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
20FR12B
yjqc1ani
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
DRS/A
kp6up1u
16 Nov 18
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next